Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History

BiOasis Technologies Inc V.BTI

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s):  BIOAF

biOasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders.
Price: $0.87 | Change: $0.00 | %Change: 0.00%
Volume: 64,200 | Day High/Low: 0.88/0.86 | 52 Week High/Low: 1.35/0.67
View modes: 
5 stars

RE:RE:RE:RE:RE:RE:RE:RE:RE:Docs

ya I felt stupid after I posted the question and went on the hunt on a ton of other 52 week targets I saw and they were a joke or even completely not even close.....  rate and reply
5 stars

RE:RE:RE:RE:RE:RE:RE:RE:Docs

I have a big answer: because it means NOTHING, Don't read that junk.  rate and reply
3.5 stars

RE:RE:RE:RE:RE:RE:RE:Docs

I have a huge question...why does the one year TARGET ON YAHOO FINACE IN THE USA SAY 15.00$.....while here we have no target in Canada yahoo finance...just curiouse  rate and reply
0 stars

RE:RE:RE:RE:RE:RE:Docs

The waiting is the worst....thanks for that j.d.....the reply inmean  rate and reply
0 stars

RE:RE:RE:RE:RE:RE:RE:Docs

Very interesting, derekiz. Their lead drug is  tozadenant (SYN115) for Parkinson's disease. It's a small molecule that can cross the BBB. Biotie also had a relationship with UCB for this drug but UCB...read more
0 stars

RE:RE:RE:RE:RE:RE:Docs

JD there's a Finnish company "Biotie Therapies" that has quite a pipeline related to therapeutic agents to the brain and CNS. Even a Parkinsons therapy set to begin PIII trials. Don't know if their...read more
3.5 stars

RE:RE:RE:RE:RE:Docs

Here's how collaborations can unfold, oilpatch. . biOasis and pharmaceutical company agree to a collaboration so that pharma can see for themselves that Transcend (p97) works as described. The...read more
0 stars

RE:RE:RE:RE:Docs

darnit, says, "Too bad they couldn't bring themselves to give a one paragraph executive summary." LOL. Most people reading this forum make an hourly wage from zero (the retired) to a few hundred...read more
0 stars

RE:RE:RE:RE:Docs

So what happened? ??..ucb didnt like our vectors? ....results were not good enough???...or what about abbvie????....texas tech results looked like they were incredible! !!!!!!!!! They eradicated 2/3...read more
0 stars

RE:RE:RE:Docs

That is one laborious and obfuscurial tomb. Too bad they couldn't bring themselves to give a one paragraph executive summary.  rate and reply
3.5 stars

RE:Docs

UCB Pharma SA The collaboration was completed in December 2013 AbbVie Inc.  The collaboration with Abbvie completed in January of 2014  rate and reply
0 stars

RE:RE:Docs

thanks for posting the link kayacker...  rate and reply
0.5 stars

RE:Docs

reads as thoug the studies at meddimune are complete and now they are sitting down deciphering the information.......hopefully we get some clarification soon  rate and reply
0 stars

Docs

New docs posted today, including an MD&A.  rate and reply
1 star

RE:siRNA is hot!

that's one way to silence the board! drj  rate and reply
5 stars

siRNA is hot!

ALNY has a $7.3 billion market cap and no drug has completed phase III. Hopefully this helps BTI when it releases its stroke and ALS data. Scale: 1d 5d 3m 6m 1y 2y 5y Type: Line Area OHLC  rate and reply
3 stars

RE:RE:RE:RE:Accountability

I profusely apologize to you, Sir_Holler. I read the quote you posted as if it were your own and that was a mistake on my part. It is a pleasure to be in agreement with you on the matter. I have a...read more
4.5 stars

RE:RE:RE:Accountability

"Sir_Holler, I catagorically refute your contention that only a deal with money attached will move the stock. It shows a complete lack of imagination and knowledge on your part about how biotechs are...read more
3.5 stars

RE:RE:Accountability

Sir_Holler, I catagorically refute your contention that only a deal with money attached will move the stock. It shows a complete lack of imagination and knowledge on your part about how biotechs are...read more
5 stars

RE:RE:RE:RE:RE:Accountability

The next stage is to reveal it to the world: "Our recent discovery and subsequent validation of Transcend(pep) as a carrier or shuttle of therapeutics into the brain are extremely encouraging. We...read more

How to invest in private equity without writing a $1 million check.

Click here to watch the video